AU2018395100B2 - Completely humanized monoclonal neutralizing antibody for tetanus toxin and application thereof - Google Patents

Completely humanized monoclonal neutralizing antibody for tetanus toxin and application thereof Download PDF

Info

Publication number
AU2018395100B2
AU2018395100B2 AU2018395100A AU2018395100A AU2018395100B2 AU 2018395100 B2 AU2018395100 B2 AU 2018395100B2 AU 2018395100 A AU2018395100 A AU 2018395100A AU 2018395100 A AU2018395100 A AU 2018395100A AU 2018395100 B2 AU2018395100 B2 AU 2018395100B2
Authority
AU
Australia
Prior art keywords
seq
monoclonal antibody
antigen
neutralizing monoclonal
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018395100A
Other languages
English (en)
Other versions
AU2018395100A1 (en
Inventor
Huaxin Liao
Yueming Wang
Xiaohui Yuan
Weihong Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhuhai Trinomab Pharmaceutical Co Ltd
Original Assignee
Zhuhai Trinomab Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201711482969.7A external-priority patent/CN108218984B/zh
Priority claimed from CN201711486732.6A external-priority patent/CN108314731B/zh
Priority claimed from CN201711486693.XA external-priority patent/CN108314730B/zh
Priority claimed from CN201810420730.5A external-priority patent/CN108623681B/zh
Application filed by Zhuhai Trinomab Pharmaceutical Co Ltd filed Critical Zhuhai Trinomab Pharmaceutical Co Ltd
Publication of AU2018395100A1 publication Critical patent/AU2018395100A1/en
Assigned to Zhuhai Trinomab Pharmaceutical Co., Ltd. reassignment Zhuhai Trinomab Pharmaceutical Co., Ltd. Amend patent request/document other than specification (104) Assignors: ZHUHAI TRINOMAB BIOTECHNOLOGY CO., LTD.
Application granted granted Critical
Publication of AU2018395100B2 publication Critical patent/AU2018395100B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2018395100A 2017-12-29 2018-12-28 Completely humanized monoclonal neutralizing antibody for tetanus toxin and application thereof Active AU2018395100B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201711482969.7A CN108218984B (zh) 2017-12-29 2017-12-29 一种抗破伤风毒素的全人源中和抗体
CN201711486732.6A CN108314731B (zh) 2017-12-29 2017-12-29 一种针对破伤风毒素的全人源单克隆中和抗体及其应用
CN201711486693.X 2017-12-29
CN201711482969.7 2017-12-29
CN201711486732.6 2017-12-29
CN201711486693.XA CN108314730B (zh) 2017-12-29 2017-12-29 抗破伤风毒素中和抗体及其制备与应用
CN201810420730.5 2018-05-04
CN201810420730.5A CN108623681B (zh) 2018-05-04 2018-05-04 一种抗破伤风毒素的中和抗体及应用
PCT/CN2018/124958 WO2019129214A1 (zh) 2017-12-29 2018-12-28 针对破伤风毒素的全人源单克隆中和抗体及其应用

Publications (2)

Publication Number Publication Date
AU2018395100A1 AU2018395100A1 (en) 2020-07-23
AU2018395100B2 true AU2018395100B2 (en) 2025-01-23

Family

ID=67063214

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018395100A Active AU2018395100B2 (en) 2017-12-29 2018-12-28 Completely humanized monoclonal neutralizing antibody for tetanus toxin and application thereof

Country Status (6)

Country Link
US (1) US11725046B2 (https=)
EP (1) EP3733699A4 (https=)
JP (1) JP7368670B2 (https=)
AU (1) AU2018395100B2 (https=)
BR (1) BR112020013094A2 (https=)
WO (1) WO2019129214A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118139879A (zh) * 2021-09-07 2024-06-04 生物医学研究院 结合破伤风毒素的抗体及其用途
CN114044819B (zh) * 2021-09-29 2024-07-12 上海儒克生物科技有限公司 全羊源单克隆抗体的高通量制备方法
CN119700969A (zh) * 2023-09-27 2025-03-28 珠海泰诺麦博制药股份有限公司 一种抗破伤风毒素抗体在预防或治疗破伤风中的应用
CN118812707B (zh) * 2024-09-20 2024-12-31 北京科兴中维生物技术有限公司 抗破伤风毒素抗体及应用
CN120829503B (zh) * 2025-09-18 2025-12-26 北京科兴中维生物技术有限公司 抗破伤风毒素抗体及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0562132A1 (en) * 1992-03-23 1993-09-29 SCHWEIZERISCHES SERUM- & IMPFINSTITUT BERN Monoclonal anti-tetanus toxin antibodies and pharmaceutical compositions containing them
JP2001299360A (ja) * 2000-04-28 2001-10-30 Morihiro Matsuda ヒト型抗破傷風毒素一本鎖組換え抗体フラグメント

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2627076B2 (ja) * 1988-08-19 1997-07-02 森永製菓株式会社 抗破傷風毒素ヒト型モノクローナル抗体、それを利用した破傷風毒素中和剤及びヒト型モノクローナル抗体産生ハイブリドーマ
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
CN1305904C (zh) 2003-12-30 2007-03-21 龚小迪 人源的抗破伤风毒素单克隆抗体的制备和应用
CN101220096B (zh) * 2003-12-30 2010-09-29 龚小迪 人源抗破伤风毒素单克隆抗体的制备和应用
CN105153305B (zh) * 2015-06-26 2019-03-01 安泰吉（北京）生物技术有限公司 一种全人源抗破伤风毒素单克隆抗体及其衍生物制备方法和应用
CN108314731B (zh) * 2017-12-29 2019-02-12 珠海泰诺麦博生物技术有限公司 一种针对破伤风毒素的全人源单克隆中和抗体及其应用
CN108314730B (zh) * 2017-12-29 2019-01-08 珠海泰诺麦博生物技术有限公司 抗破伤风毒素中和抗体及其制备与应用
CN108218984B (zh) * 2017-12-29 2018-10-26 珠海泰诺麦博生物技术有限公司 一种抗破伤风毒素的全人源中和抗体
CN108623681B (zh) * 2018-05-04 2019-05-24 珠海泰诺麦博生物技术有限公司 一种抗破伤风毒素的中和抗体及应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0562132A1 (en) * 1992-03-23 1993-09-29 SCHWEIZERISCHES SERUM- & IMPFINSTITUT BERN Monoclonal anti-tetanus toxin antibodies and pharmaceutical compositions containing them
JP2001299360A (ja) * 2000-04-28 2001-10-30 Morihiro Matsuda ヒト型抗破傷風毒素一本鎖組換え抗体フラグメント

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHIN J ET AL: "Production of neutralizing human monoclonal antibody directed to tetanus toxin in CHO cell", BIOLOGICALS, ACADEMIC PRESS LTD., LONDON, GB, vol. 31, no. 1, 1 March 2003 (2003-03-01), pages 45 - 53. *

Also Published As

Publication number Publication date
AU2018395100A1 (en) 2020-07-23
EP3733699A1 (en) 2020-11-04
US11725046B2 (en) 2023-08-15
JP7368670B2 (ja) 2023-10-25
WO2019129214A1 (zh) 2019-07-04
JP2021508495A (ja) 2021-03-11
EP3733699A4 (en) 2022-06-08
BR112020013094A2 (pt) 2021-03-30
US20210002356A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
AU2018395100B2 (en) Completely humanized monoclonal neutralizing antibody for tetanus toxin and application thereof
JP7747353B2 (ja) 抗コロナウイルス完全ヒト広域スペクトル中和抗体７６ｅ１及びその適用
CN108218984B (zh) 一种抗破伤风毒素的全人源中和抗体
CN114390938A (zh) 受约束的条件性活化的结合蛋白
US20250042957A1 (en) Designed repeat domains with dual binding specificity and their use
CN117402243A (zh) 抗Nectin-4抗体及其应用
KR102663963B1 (ko) 코로나-19 바이러스 표적 인간 항체
JP2017526686A (ja) ＯｐｒＦおよびＯｐｒＩに結合する抗体医薬
CN112225813B (zh) 针对破伤风毒素的抗体及其用途
CN108314730A (zh) 抗破伤风毒素中和抗体及其制备与应用
SG178503A1 (en) New antibiotic containing simulacrum antibody, preparation method and application thereof
US20240199725A1 (en) Human antibody targeting covid-19 virus
US8507655B2 (en) Antibody against anthrax toxins
US20240360216A1 (en) Anti-cd3 humanized antibody
JP2015534998A (ja) Ａｉｐ２を結合する抗感染症結合タンパク質
CN108623681A (zh) 一种抗破伤风毒素的中和抗体及应用
CN121152799A (zh) 抗白介素18受体的纳米抗体及其应用
AU2008332943B2 (en) G immunoglobulin used against anthrax toxins
RU2815280C1 (ru) Антитело против столбнячного токсина и его применение
US20220080036A1 (en) Human monoclonal antibodies to staphylococcal aureus isd proteins and uses thereof
US20120171122A1 (en) Loop-Variant Pdz Domains As Biotherapeutics, Diagnostics And Research Reagents
ES2951019B2 (es) Anticuerpo inhibidor de B-lactamasa y uso para el tratamiento y/o prevención de infecciones causadas por bacterias que producen B-lactamasas
Wang et al. A new neutralizing antibody against botulinum neurotoxin B recognizes the protein receptor binding sites for synaptotagmins II
WO2024119065A9 (en) Anti-mesothelin bispecific antibodies and methods of use
EP4598961A1 (en) Glypican 3 antibody and related methods

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ZHUHAI TRINOMAB PHARMACEUTICAL CO., LTD.

Free format text: FORMER NAME(S): ZHUHAI TRINOMAB BIOTECHNOLOGY CO., LTD.

FGA Letters patent sealed or granted (standard patent)